eligibility_summary
Newly diagnosed CD30+ PTCL (ALK± sALCL [ALK+ IPI≥2], PTCL‑NOS, AITL, EATL, HSTCL), ECOG≤2, FDG‑avid measurable disease (>1.5 cm). Adequate organ function: bili ≤1.5×ULN (≤3× Gilbert’s/liver), ALT/AST ≤3× (≤5× hepatic), creatinine <2 mg/dL or CrCl>40, Hgb≥8, ANC>1.5, Plt≥75. Exclude: prior systemic therapy, major surgery<28d, HIV, active HBV/HCV (HBcAb+ if DNA−), other cancer ≤3y, cardiac disease, primary cutaneous CD30+ or MF, uncontrolled DM, neuropathy ≥G2, PML, prior brentuximab.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05673785: Phase 2, single-arm frontline study in China of A+CHP for CD30+ peripheral T‑cell lymphomas. Drugs/mechanisms: Brentuximab vedotin (antibody–drug conjugate, anti‑CD30 mAb linked to MMAE) binds CD30 on malignant T cells, is internalized, and releases MMAE to disrupt microtubules causing mitotic arrest/apoptosis (may also mediate ADCC). Cyclophosphamide (alkylating agent) crosslinks DNA. Doxorubicin (anthracycline) intercalates DNA and inhibits topoisomerase II, generating ROS and DNA breaks. Prednisone (glucocorticoid) induces apoptosis of lymphoid cells. Targets/pathways: CD30 on PTCL cells, microtubules, DNA crosslinking and Topo II–mediated DNA damage, glucocorticoid receptor signaling.